Pre-made Cinrebafusp Alfa benchmark antibody (Bispecific, anti-ERBB2/HER2;TNFRSF9/CD137 therapeutic antibody, Anti-CD340/MLN 19/NEU/NGL/TKR1/VSCN2;ILA/4-1BB/CDw137 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Cinrebafusp Alfa benchmark antibody (Bispecific, anti-ERBB2/HER2;TNFRSF9/CD137 therapeutic antibody, Anti-CD340/MLN 19/NEU/NGL/TKR1/VSCN2;ILA/4-1BB/CDw137 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

cinrebafusp alfa (PRS-343), is a bispecific fusion protein that combines a 4-1BB-targeting Anticalin protein and a HER2-targeting antibody. 4-1BB is an immunoreceptor that powerfully enhances T cell proliferation, survival, and activity.
Cinrebafusp alfa bridges 4-1BB immune cells with HER2-expressing tumor cells, causing the immune cells to cluster around cancerous cells. By combining a 4-1BB-targeting Anticalin proteinwith a HER2-targeting antibody, cinrebafusp alfa focuses 4-1BB activation locally on the tumor, increasing the efficiency of the immune response and reducing systemic toxicity, compared to 4-1BB-targeting antibodies alone.
Cinrebafusp alfa has shown both clinical benefit linked to a 4-1BB mechanism of action, and robust durability, and has been observed to be safe and well-tolerated at all doses and schedules tested.